|
gptkbp:instanceOf
|
gptkb:drug
gptkb:acetylcholinesterase_inhibitor
butyrylcholinesterase inhibitor
|
|
gptkbp:administeredBy
|
capsule
oral solution
transdermal patch
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06DA03
|
|
gptkbp:brand
|
gptkb:Exelon
Prometax
|
|
gptkbp:CASNumber
|
gptkb:123441-03-2
|
|
gptkbp:chemicalClass
|
carbamate
|
|
gptkbp:contraindication
|
hypersensitivity to rivastigmine
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
1.5 hours (oral)
3 hours (patch)
|
|
gptkbp:hasMolecularFormula
|
C14H22N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rivastigmina
|
|
gptkbp:KEGGID
|
D08445
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits acetylcholinesterase and butyrylcholinesterase
|
|
gptkbp:MedlinePlusID
|
a699058
|
|
gptkbp:metabolism
|
plasma esterases
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
40%
|
|
gptkbp:PubChem_CID
|
CHEMBL1387
77991
DB00989
|
|
gptkbp:routeOfAdministration
|
oral
transdermal patch
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
dizziness
headache
loss of appetite
weight loss
|
|
gptkbp:synonym
|
Rivastigmine
|
|
gptkbp:UNII
|
7G33012534
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease_dementia
|
|
gptkbp:bfsParent
|
gptkb:rivastigmine
|
|
gptkbp:bfsLayer
|
8
|